Abacavir and risk of myocardial infarction in HIV‐infected patients on highly active antiretroviral therapy: a population‐based nationwide cohort study
Objective The aim of the study was to examine whether exposure to abacavir increases the risk for myocardial infarction (MI). Design, setting and subjects This was a prospective nationwide cohort study which included all Danish HIV‐infected patients on highly active antiretroviral therapy (HAART) fr...
Saved in:
Published in | HIV medicine Vol. 11; no. 2; pp. 130 - 136 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.02.2010
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objective
The aim of the study was to examine whether exposure to abacavir increases the risk for myocardial infarction (MI).
Design, setting and subjects
This was a prospective nationwide cohort study which included all Danish HIV‐infected patients on highly active antiretroviral therapy (HAART) from 1995 to 2005 (N=2952). Data on hospitalization for MI and comorbidity were obtained from Danish medical databases. Hospitalization rates for MI after HAART initiation were calculated for patients who used abacavir and those who did not. We used Cox's regression to compute incidence rate ratios (IRR) as a measure of relative risk for MI, while controlling for potential confounders (as separate variables and via propensity score) including comorbidity.
Main outcome
Relative risk of hospitalization with MI in abacavir users compared with abacavir nonusers.
Results
Hospitalization rates for MI were 2.4/1000 person‐years (PYR) [95% confidence interval (CI) 1.7–3.4] for abacavir nonusers and 5.7/1000 PYR (95% CI 4.1–7.9) for abacavir users. The risk of MI increased after initiation of abacavir [unadjusted IRR=2.22 (95% CI 1.31–3.76); IRR adjusted for confounders=2.00 (95% CI 1.10–3.64); IRR adjusted for propensity score=2.00 (95% CI 1.07–3.76)]. This effect was also observed among patients initiating abacavir within 2 years after the start of HAART and among patients who started abacavir as part of a triple nucleoside reverse transcriptase inhibitor (NRTI) regimen.
Conclusions
We confirmed the association between abacavir use and increased risk of MI. Further studies are needed to control for potential confounding not measured in research to date. |
---|---|
AbstractList | Objective
The aim of the study was to examine whether exposure to abacavir increases the risk for myocardial infarction (MI).
Design, setting and subjects
This was a prospective nationwide cohort study which included all Danish HIV‐infected patients on highly active antiretroviral therapy (HAART) from 1995 to 2005 (N=2952). Data on hospitalization for MI and comorbidity were obtained from Danish medical databases. Hospitalization rates for MI after HAART initiation were calculated for patients who used abacavir and those who did not. We used Cox's regression to compute incidence rate ratios (IRR) as a measure of relative risk for MI, while controlling for potential confounders (as separate variables and via propensity score) including comorbidity.
Main outcome
Relative risk of hospitalization with MI in abacavir users compared with abacavir nonusers.
Results
Hospitalization rates for MI were 2.4/1000 person‐years (PYR) [95% confidence interval (CI) 1.7–3.4] for abacavir nonusers and 5.7/1000 PYR (95% CI 4.1–7.9) for abacavir users. The risk of MI increased after initiation of abacavir [unadjusted IRR=2.22 (95% CI 1.31–3.76); IRR adjusted for confounders=2.00 (95% CI 1.10–3.64); IRR adjusted for propensity score=2.00 (95% CI 1.07–3.76)]. This effect was also observed among patients initiating abacavir within 2 years after the start of HAART and among patients who started abacavir as part of a triple nucleoside reverse transcriptase inhibitor (NRTI) regimen.
Conclusions
We confirmed the association between abacavir use and increased risk of MI. Further studies are needed to control for potential confounding not measured in research to date. The aim of the study was to examine whether exposure to abacavir increases the risk for myocardial infarction (MI). This was a prospective nationwide cohort study which included all Danish HIV-infected patients on highly active antiretroviral therapy (HAART) from 1995 to 2005 (N = 2952). Data on hospitalization for MI and comorbidity were obtained from Danish medical databases. Hospitalization rates for MI after HAART initiation were calculated for patients who used abacavir and those who did not. We used Cox's regression to compute incidence rate ratios (IRR) as a measure of relative risk for MI, while controlling for potential confounders (as separate variables and via propensity score) including comorbidity. Relative risk of hospitalization with MI in abacavir users compared with abacavir nonusers. Hospitalization rates for MI were 2.4/1000 person-years (PYR) [95% confidence interval (CI) 1.7-3.4] for abacavir nonusers and 5.7/1000 PYR (95% CI 4.1-7.9) for abacavir users. The risk of MI increased after initiation of abacavir [unadjusted IRR = 2.22 (95% CI 1.31-3.76); IRR adjusted for confounders = 2.00 (95% CI 1.10-3.64); IRR adjusted for propensity score = 2.00 (95% CI 1.07-3.76)]. This effect was also observed among patients initiating abacavir within 2 years after the start of HAART and among patients who started abacavir as part of a triple nucleoside reverse transcriptase inhibitor (NRTI) regimen. We confirmed the association between abacavir use and increased risk of MI. Further studies are needed to control for potential confounding not measured in research to date. OBJECTIVEThe aim of the study was to examine whether exposure to abacavir increases the risk for myocardial infarction (MI).DESIGN, SETTING AND SUBJECTSThis was a prospective nationwide cohort study which included all Danish HIV-infected patients on highly active antiretroviral therapy (HAART) from 1995 to 2005 (N = 2952). Data on hospitalization for MI and comorbidity were obtained from Danish medical databases. Hospitalization rates for MI after HAART initiation were calculated for patients who used abacavir and those who did not. We used Cox's regression to compute incidence rate ratios (IRR) as a measure of relative risk for MI, while controlling for potential confounders (as separate variables and via propensity score) including comorbidity.MAIN OUTCOMERelative risk of hospitalization with MI in abacavir users compared with abacavir nonusers.RESULTSHospitalization rates for MI were 2.4/1000 person-years (PYR) [95% confidence interval (CI) 1.7-3.4] for abacavir nonusers and 5.7/1000 PYR (95% CI 4.1-7.9) for abacavir users. The risk of MI increased after initiation of abacavir [unadjusted IRR = 2.22 (95% CI 1.31-3.76); IRR adjusted for confounders = 2.00 (95% CI 1.10-3.64); IRR adjusted for propensity score = 2.00 (95% CI 1.07-3.76)]. This effect was also observed among patients initiating abacavir within 2 years after the start of HAART and among patients who started abacavir as part of a triple nucleoside reverse transcriptase inhibitor (NRTI) regimen.CONCLUSIONSWe confirmed the association between abacavir use and increased risk of MI. Further studies are needed to control for potential confounding not measured in research to date. Objective The aim of the study was to examine whether exposure to abacavir increases the risk for myocardial infarction (MI). Design, setting and subjects This was a prospective nationwide cohort study which included all Danish HIV‐infected patients on highly active antiretroviral therapy (HAART) from 1995 to 2005 ( N =2952). Data on hospitalization for MI and comorbidity were obtained from Danish medical databases. Hospitalization rates for MI after HAART initiation were calculated for patients who used abacavir and those who did not. We used Cox's regression to compute incidence rate ratios (IRR) as a measure of relative risk for MI, while controlling for potential confounders (as separate variables and via propensity score) including comorbidity. Main outcome Relative risk of hospitalization with MI in abacavir users compared with abacavir nonusers. Results Hospitalization rates for MI were 2.4/1000 person‐years (PYR) [95% confidence interval (CI) 1.7–3.4] for abacavir nonusers and 5.7/1000 PYR (95% CI 4.1–7.9) for abacavir users. The risk of MI increased after initiation of abacavir [unadjusted IRR=2.22 (95% CI 1.31–3.76); IRR adjusted for confounders=2.00 (95% CI 1.10–3.64); IRR adjusted for propensity score=2.00 (95% CI 1.07–3.76)]. This effect was also observed among patients initiating abacavir within 2 years after the start of HAART and among patients who started abacavir as part of a triple nucleoside reverse transcriptase inhibitor (NRTI) regimen. Conclusions We confirmed the association between abacavir use and increased risk of MI. Further studies are needed to control for potential confounding not measured in research to date. |
Author | Farkas, DK Riis, A Sørensen, HT Pedersen, C Obel, N Larsen, CS Gerstoft, J Pedersen, G Kronborg, G |
Author_xml | – sequence: 1 givenname: N surname: Obel fullname: Obel, N – sequence: 2 givenname: DK surname: Farkas fullname: Farkas, DK – sequence: 3 givenname: G surname: Kronborg fullname: Kronborg, G – sequence: 4 givenname: CS surname: Larsen fullname: Larsen, CS – sequence: 5 givenname: G surname: Pedersen fullname: Pedersen, G – sequence: 6 givenname: A surname: Riis fullname: Riis, A – sequence: 7 givenname: C surname: Pedersen fullname: Pedersen, C – sequence: 8 givenname: J surname: Gerstoft fullname: Gerstoft, J – sequence: 9 givenname: HT surname: Sørensen fullname: Sørensen, HT |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19682101$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkc9u1DAQhy1URP_AKyDfOCV44sRJEJeqKrRSJS7A1ZrYDuslGwfbaZsbj8Cdt-NJcHZXcARfPOP5zefDd05ORjcaQiiwHNJ5vc2hFE0GRcvzgrE2Z6yuIH98Qs7-DE72dZkVQhSn5DyELWNQ85Y9I6fQiqYABmfk52WHCu-tpzhq6m34Sl1Pd4tT6LXFgdqxR6-idWMq6c3t51_ff6Q3o6LRdMJozRgDTdON_bIZFoope28SLVpvoncJnShxYzxOyxuKdHLTPOAKTKQOQ8KM-_bBakOV2zgfaYizXp6Tpz0Owbw43hfk07vrj1c32d2H97dXl3eZKssWMiGaumM100JXmveNwrJkwhgQXOmO9T2DrkeeQqYtO4VQ14XQpqqAc8CK8Qvy6sCdvPs2mxDlzgZlhgFH4-YgW6h4Axzgn8malwUHwdqUbA5J5V0I3vRy8naHfpHA5OpQbuWqSq6q5OpQ7h3Kx7T68vjJ3O2M_rt4lJYCbw-BBzuY5b_BMslLBf8NIf-xUQ |
CitedBy_id | crossref_primary_10_1097_EDE_0000000000000041 crossref_primary_10_1097_QAD_0b013e328354f4fb crossref_primary_10_1097_QAI_0b013e31826f993c crossref_primary_10_1007_s15010_015_0795_5 crossref_primary_10_1371_journal_pone_0049289 crossref_primary_10_1186_s12906_023_04300_5 crossref_primary_10_1136_bmjopen_2018_025874 crossref_primary_10_1093_cid_cir829 crossref_primary_10_1111_hiv_12116 crossref_primary_10_2174_1874613601509010023 crossref_primary_10_3851_IMP1891 crossref_primary_10_1007_s12325_010_0006_9 crossref_primary_10_1097_QAD_0000000000001547 crossref_primary_10_1089_aid_2012_0034 crossref_primary_10_1097_QAD_0b013e32833a2b02 crossref_primary_10_1097_MD_0000000000025428 crossref_primary_10_1097_QAI_0000000000002633 crossref_primary_10_1016_j_coviro_2016_03_004 crossref_primary_10_1093_cid_ciq244 crossref_primary_10_1093_ofid_ofy086 crossref_primary_10_1016_j_antiviral_2016_05_015 crossref_primary_10_2217_fvl_2016_0047 crossref_primary_10_1016_j_bjid_2013_05_004 crossref_primary_10_1071_SH11020 crossref_primary_10_1093_cid_civ013 crossref_primary_10_1093_cid_civ016 crossref_primary_10_11622_smedj_2021174 crossref_primary_10_1016_j_idc_2014_06_003 crossref_primary_10_1097_QAD_0b013e328337afdf crossref_primary_10_1186_s12879_016_1735_4 crossref_primary_10_1111_bph_16016 crossref_primary_10_1097_QAD_0000000000002244 crossref_primary_10_1111_j_1468_1293_2012_01029_6_x crossref_primary_10_1097_COH_0000000000000019 crossref_primary_10_1097_COH_0000000000000410 crossref_primary_10_1371_journal_pone_0059551 crossref_primary_10_1080_14656566_2016_1232387 crossref_primary_10_1097_COH_0b013e328354dcac crossref_primary_10_1111_j_1468_1293_2012_00996_x crossref_primary_10_1093_cid_ciu617 crossref_primary_10_1080_14656566_2017_1377181 crossref_primary_10_3390_microorganisms11040958 crossref_primary_10_1071_SH12081 crossref_primary_10_1186_s41824_019_0053_7 crossref_primary_10_1177_1060028021995586 crossref_primary_10_3390_ph13060122 crossref_primary_10_1097_QAD_0b013e32834bab9e crossref_primary_10_1007_s11904_017_0356_x crossref_primary_10_1097_QAI_0000000000001642 crossref_primary_10_1111_hiv_12043 crossref_primary_10_1007_s11904_010_0047_3 crossref_primary_10_1093_cid_civ316 crossref_primary_10_3390_diagnostics12123147 crossref_primary_10_1111_j_1468_1293_2012_01029_9_x crossref_primary_10_3851_IMP2651 crossref_primary_10_1007_s40121_022_00630_y crossref_primary_10_1093_aje_kwu010 crossref_primary_10_1097_QAD_0b013e3283493fb0 crossref_primary_10_1097_QAI_0000000000000662 crossref_primary_10_2174_1570162X18666200106150806 crossref_primary_10_2174_1570162X18666210111102046 crossref_primary_10_3851_IMP2020 crossref_primary_10_1111_tmi_13405 crossref_primary_10_1186_s12916_016_0588_4 crossref_primary_10_1002_prp2_776 crossref_primary_10_1016_S0140_6736_12_62004_2 crossref_primary_10_1007_s11904_015_0284_6 crossref_primary_10_1089_apc_2011_0199 crossref_primary_10_1177_2050312117725644 crossref_primary_10_1007_s11136_017_1519_3 crossref_primary_10_1093_cid_ciad728 crossref_primary_10_1111_hiv_12426 crossref_primary_10_2217_fvl_12_25 crossref_primary_10_1016_j_ijantimicag_2018_07_010 crossref_primary_10_1111_hiv_12119_6 crossref_primary_10_1161_ATVBAHA_120_315435 crossref_primary_10_1186_s12879_017_2692_2 crossref_primary_10_1016_j_antiviral_2017_03_001 crossref_primary_10_1097_QAD_0b013e32834d3cc3 crossref_primary_10_3389_fimmu_2023_1182942 crossref_primary_10_3389_fphys_2023_1118653 crossref_primary_10_1089_aid_2020_0053 crossref_primary_10_2217_hiv_10_53 crossref_primary_10_1093_cid_ciz373 crossref_primary_10_1371_journal_pone_0254079 crossref_primary_10_1371_journal_pone_0117164 crossref_primary_10_1371_journal_pone_0123043 crossref_primary_10_1093_ofid_ofaa340 crossref_primary_10_1097_QAI_0000000000000881 crossref_primary_10_1097_COH_0000000000000614 crossref_primary_10_1186_s12879_017_2808_8 crossref_primary_10_1097_QAD_0000000000003373 crossref_primary_10_1097_QAI_0000000000000009 crossref_primary_10_37336_2707_0700_2019_3_5 crossref_primary_10_1016_j_eimc_2013_04_009 crossref_primary_10_1155_2016_3420638 crossref_primary_10_1093_cid_cir269 crossref_primary_10_1097_COH_0b013e328354da1d crossref_primary_10_1089_jwh_2015_5736 crossref_primary_10_1093_jac_dky383 crossref_primary_10_1097_QAD_0000000000001088 crossref_primary_10_1093_infdis_jir509 crossref_primary_10_1111_hiv_12119_9 |
Cites_doi | 10.1093/ije/dyn192 10.1126/science.287.5462.2398 10.1056/NEJMoa030218 10.1111/j.1742-7843.2006.pto_293.x 10.1093/eurheartj/ehi039 10.1056/NEJMoa062744 10.1097/00126334-200305010-00005 10.1097/00126334-200305010-00004 10.1097/ACI.0b013e32825ea68a 10.1097/00002030-200305230-00010 10.1086/430379 10.1002/sim.4780100409 10.7326/0003-4819-146-2-200701160-00003 10.1056/NEJMp078038 10.1016/S0140-6736(08)60492-4 10.1086/528862 10.1097/01.aids.0000247574.33998.03 10.1097/QAD.0b013e32830fe35e 10.1056/NEJMoa0707064 |
ContentType | Journal Article |
Copyright | 2009 British HIV Association |
Copyright_xml | – notice: 2009 British HIV Association |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7U9 H94 |
DOI | 10.1111/j.1468-1293.2009.00751.x |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Virology and AIDS Abstracts AIDS and Cancer Research Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic AIDS and Cancer Research Abstracts Virology and AIDS Abstracts |
DatabaseTitleList | MEDLINE MEDLINE - Academic AIDS and Cancer Research Abstracts CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1468-1293 |
EndPage | 136 |
ExternalDocumentID | 10_1111_j_1468_1293_2009_00751_x 19682101 HIV751 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Denmark |
GeographicLocations_xml | – name: Denmark |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1OC 24P 29I 2WC 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EAS EBC EBD EBS EJD EMB EMK EMOBN EPT ESX EX3 F00 F01 F04 F5P FIJ FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 Q~Q R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WVDHM WXI WXSBR XG1 YFH ZZTAW ~IA ~WT ACXME CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7U9 H94 |
ID | FETCH-LOGICAL-c4491-6687b070d6d5d3f8ca4406ee163cdb0ff01bfa387be94bca17726de551331a503 |
IEDL.DBID | DR2 |
ISSN | 1464-2662 |
IngestDate | Sat Aug 17 01:03:56 EDT 2024 Fri Aug 16 07:58:28 EDT 2024 Fri Aug 23 03:42:05 EDT 2024 Thu May 23 23:14:45 EDT 2024 Sat Aug 24 01:19:21 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4491-6687b070d6d5d3f8ca4406ee163cdb0ff01bfa387be94bca17726de551331a503 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1468-1293.2009.00751.x |
PMID | 19682101 |
PQID | 734231609 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_915381311 proquest_miscellaneous_734231609 crossref_primary_10_1111_j_1468_1293_2009_00751_x pubmed_primary_19682101 wiley_primary_10_1111_j_1468_1293_2009_00751_x_HIV751 |
PublicationCentury | 2000 |
PublicationDate | February 2010 2010-Feb 2010-02-00 20100201 |
PublicationDateYYYYMMDD | 2010-02-01 |
PublicationDate_xml | – month: 02 year: 2010 text: February 2010 |
PublicationDecade | 2010 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: England |
PublicationTitle | HIV medicine |
PublicationTitleAlternate | HIV Med |
PublicationYear | 2010 |
Publisher | Blackwell Publishing Ltd |
Publisher_xml | – name: Blackwell Publishing Ltd |
References | 2007; 356 2007; 146 2006; 41 2003; 349 2006; 20 2002; 31 2006; 98 1991; 10 2002; 288 1999; 46 2005; 40 2008 2008; 46 2007; 7 2003; 17 2008; 358 2008; 22 2000; 287 2005; 37 2005; 26 2007; 44 2008; 371 2003; 33 Obel N (e_1_2_6_3_2) 2007; 44 Bernasconi E (e_1_2_6_16_2) 2002; 31 Carr A (e_1_2_6_22_2) 2002; 288 e_1_2_6_18_2 e_1_2_6_19_2 Sabin CA (e_1_2_6_7_2) 2008; 371 e_1_2_6_13_2 e_1_2_6_10_2 e_1_2_6_11_2 e_1_2_6_17_2 e_1_2_6_14_2 e_1_2_6_15_2 Berenguer J (e_1_2_6_23_2) 2006; 41 Podzamczer D (e_1_2_6_20_2) 2007; 44 Lohse N (e_1_2_6_9_2) 2005; 37 e_1_2_6_8_2 Andersen TF (e_1_2_6_12_2) 1999; 46 e_1_2_6_4_2 e_1_2_6_6_2 e_1_2_6_5_2 e_1_2_6_24_2 e_1_2_6_2_2 e_1_2_6_21_2 e_1_2_6_28_2 e_1_2_6_27_2 e_1_2_6_26_2 e_1_2_6_25_2 |
References_xml | – volume: 17 start-page: 1179 year: 2003 end-page: 1193 article-title: Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD Study publication-title: AIDS – volume: 22 start-page: F17 year: 2008 end-page: F24 article-title: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV‐infected patients publication-title: AIDS – volume: 41 start-page: 154 year: 2006 end-page: 159 article-title: Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy‐naïve HIV‐infected patients publication-title: results from a large multicenter observational cohort – volume: 146 start-page: 87 year: 2007 end-page: 95 article-title: Survival of persons with and without HIV infection in Denmark, 1995–2005 publication-title: Ann Intern Med – volume: 20 start-page: 2043 year: 2006 end-page: 2050 article-title: A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy publication-title: AIDS – volume: 349 start-page: 1993 year: 2003 end-page: 2003 article-title: Combination antiretroviral therapy and the risk of myocardial infarction publication-title: N Engl J Med – volume: 358 start-page: 2107 year: 2008 end-page: 2116 article-title: Use of multiple biomarkers to improve the prediction of death from cardiovascular causes publication-title: N Engl J Med – volume: 356 start-page: 1723 year: 2007 end-page: 1735 article-title: Class of antiretroviral drugs and the risk of myocardial infarction publication-title: N Engl J Med – year: 2008 article-title: Cohort profile publication-title: The Danish HIV Cohort Study – volume: 26 start-page: 990 year: 2005 end-page: 995 article-title: Changes in hospitalization rate and mortality after acute myocardial infarction in Denmark after diagnostic criteria and methods changed publication-title: Eur Heart J – volume: 37 start-page: 338 year: 2005 end-page: 343 article-title: Demographics of HIV‐1 infection in Denmark publication-title: results from the Danish HIV Cohort Study – volume: 44 start-page: 139 year: 2007 end-page: 147 article-title: Less lipoatrophy and better lipid profile with abacavir as compared to stavudine publication-title: 96-week results of a randomized study – volume: 356 start-page: 1705 year: 2007 end-page: 1707 article-title: Challenges in using observational studies to evaluate adverse effects of treatment publication-title: N Engl J Med – volume: 33 start-page: 22 year: 2003 end-page: 28 article-title: A 48‐week, randomized, open‐label comparison of three abacavir‐based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy publication-title: J Acquir Immune Defic Syndr – volume: 10 start-page: 577 year: 1991 end-page: 581 article-title: Channeling bias in the interpretation of drug effects publication-title: Stat Med – volume: 371 start-page: 1413 year: 2008 article-title: Abacavir and the potential risk of myocardial infarction publication-title: Lancet – volume: 44 start-page: 1625 year: 2007 end-page: 1631 article-title: Ischemic heart disease in HIV‐infected and HIV‐uninfected individuals publication-title: a population-based cohort study – volume: 40 start-page: 1837 year: 2005 end-page: 1845 article-title: Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV‐infected men and women publication-title: Clin Infect Dis – volume: 33 start-page: 29 year: 2003 end-page: 33 article-title: Randomized, controlled, 48‐week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV‐infected patients publication-title: J Acquir Immune Defic Syndr – volume: 287 start-page: 2398 year: 2000 end-page: 2399 article-title: Epidemiology. When an entire country is a cohort publication-title: Science – volume: 288 start-page: 207 year: 2002 end-page: 215 article-title: Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy publication-title: a randomized trial – volume: 46 start-page: 1101 year: 2008 end-page: 1110 article-title: Changes over time in risk factors for cardiovascular disease and use of lipid‐lowering drugs in HIV‐infected individuals and impact on myocardial infarction publication-title: Clin Infect Dis – volume: 98 start-page: 253 year: 2006 end-page: 259 article-title: Indications for propensity scores and review of their use in pharmacoepidemiology publication-title: Basic Clin Pharmacol Toxicol – volume: 31 start-page: 50 year: 2002 end-page: 55 article-title: Abnormalities of body fat distribution in HIV‐infected persons treated with antiretroviral drugs publication-title: The Swiss HIV Cohort Study – volume: 46 start-page: 263 year: 1999 end-page: 268 article-title: The Danish National Hospital Register. A valuable source of data for modern health sciences publication-title: Dan Med Bull – volume: 7 start-page: 324 year: 2007 end-page: 330 article-title: Drug hypersensitivity in HIV publication-title: Curr Opin Allergy Clin Immunol – volume: 371 start-page: 1417 year: 2008 end-page: 1426 article-title: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV‐infected patients enrolled in the DAD Study publication-title: a multi-cohort collaboration – ident: e_1_2_6_10_2 doi: 10.1093/ije/dyn192 – volume: 41 start-page: 154 year: 2006 ident: e_1_2_6_23_2 article-title: Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy‐naïve HIV‐infected patients publication-title: results from a large multicenter observational cohort contributor: fullname: Berenguer J – ident: e_1_2_6_11_2 doi: 10.1126/science.287.5462.2398 – ident: e_1_2_6_5_2 doi: 10.1056/NEJMoa030218 – ident: e_1_2_6_13_2 doi: 10.1111/j.1742-7843.2006.pto_293.x – ident: e_1_2_6_14_2 doi: 10.1093/eurheartj/ehi039 – ident: e_1_2_6_6_2 doi: 10.1056/NEJMoa062744 – ident: e_1_2_6_21_2 doi: 10.1097/00126334-200305010-00005 – ident: e_1_2_6_18_2 doi: 10.1097/00126334-200305010-00004 – ident: e_1_2_6_27_2 doi: 10.1097/ACI.0b013e32825ea68a – ident: e_1_2_6_4_2 doi: 10.1097/00002030-200305230-00010 – volume: 44 start-page: 139 year: 2007 ident: e_1_2_6_20_2 article-title: Less lipoatrophy and better lipid profile with abacavir as compared to stavudine publication-title: 96-week results of a randomized study contributor: fullname: Podzamczer D – ident: e_1_2_6_17_2 doi: 10.1086/430379 – ident: e_1_2_6_24_2 doi: 10.1002/sim.4780100409 – volume: 44 start-page: 1625 year: 2007 ident: e_1_2_6_3_2 article-title: Ischemic heart disease in HIV‐infected and HIV‐uninfected individuals publication-title: a population-based cohort study contributor: fullname: Obel N – ident: e_1_2_6_2_2 doi: 10.7326/0003-4819-146-2-200701160-00003 – ident: e_1_2_6_15_2 doi: 10.1056/NEJMp078038 – ident: e_1_2_6_25_2 doi: 10.1016/S0140-6736(08)60492-4 – volume: 37 start-page: 338 year: 2005 ident: e_1_2_6_9_2 article-title: Demographics of HIV‐1 infection in Denmark publication-title: results from the Danish HIV Cohort Study contributor: fullname: Lohse N – volume: 31 start-page: 50 year: 2002 ident: e_1_2_6_16_2 article-title: Abnormalities of body fat distribution in HIV‐infected persons treated with antiretroviral drugs publication-title: The Swiss HIV Cohort Study contributor: fullname: Bernasconi E – ident: e_1_2_6_26_2 doi: 10.1086/528862 – ident: e_1_2_6_19_2 doi: 10.1097/01.aids.0000247574.33998.03 – ident: e_1_2_6_8_2 doi: 10.1097/QAD.0b013e32830fe35e – volume: 371 start-page: 1417 year: 2008 ident: e_1_2_6_7_2 article-title: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV‐infected patients enrolled in the DAD Study publication-title: a multi-cohort collaboration contributor: fullname: Sabin CA – volume: 46 start-page: 263 year: 1999 ident: e_1_2_6_12_2 article-title: The Danish National Hospital Register. A valuable source of data for modern health sciences publication-title: Dan Med Bull contributor: fullname: Andersen TF – ident: e_1_2_6_28_2 doi: 10.1056/NEJMoa0707064 – volume: 288 start-page: 207 year: 2002 ident: e_1_2_6_22_2 article-title: Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy publication-title: a randomized trial contributor: fullname: Carr A |
SSID | ssj0017390 |
Score | 2.3176477 |
Snippet | Objective
The aim of the study was to examine whether exposure to abacavir increases the risk for myocardial infarction (MI).
Design, setting and subjects
This... The aim of the study was to examine whether exposure to abacavir increases the risk for myocardial infarction (MI). This was a prospective nationwide cohort... OBJECTIVEThe aim of the study was to examine whether exposure to abacavir increases the risk for myocardial infarction (MI).DESIGN, SETTING AND SUBJECTSThis... ObjectiveThe aim of the study was to examine whether exposure to abacavir increases the risk for myocardial infarction (MI).Design, setting and subjectsThis... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 130 |
SubjectTerms | Abacavir Adult Anti-HIV Agents - adverse effects Antiretroviral Therapy, Highly Active Comorbidity Data processing Denmark - epidemiology Dideoxynucleosides - adverse effects Epidemiologic Methods Female highly active antiretroviral therapy HIV HIV Infections - drug therapy Hospitalization - statistics & numerical data Human immunodeficiency virus Humans ischemic heart disease Male Middle Aged Myocardial infarction Myocardial Infarction - chemically induced Myocardial Infarction - epidemiology Myocardial Ischemia - epidemiology nucleoside reverse transcriptase inhibitors nucleotide analogues Proportional Hazards Models Risk assessment Time Factors |
Title | Abacavir and risk of myocardial infarction in HIV‐infected patients on highly active antiretroviral therapy: a population‐based nationwide cohort study |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1468-1293.2009.00751.x https://www.ncbi.nlm.nih.gov/pubmed/19682101 https://search.proquest.com/docview/734231609 https://search.proquest.com/docview/915381311 |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwELUQh4pLS0tbln5oDlyzirOOk3BDVdG2Ej1UpeIW-VNC0OxqNwssJ34C9_67_pLO2NmtdilShXqJLMVxEueN59kZv2FsH0lqNvAlT0rnZSKyTCWqKHhivNTSZ3gQtMH5-IscnojPp_lpF_9Ee2GiPsRywY0sI4zXZOBKT9eNHGdA6K8WspNFzvvEJ0lXj_jR16WSFC8GYbkFLxEJ-qS1oJ6_NrTqqe7Rz1U2G9zR0TN2vniRGIVy3p-1um9u1jQe_8-bbrOnHWuFwwiz52zDNS_Yk-Puv_wO-3molVGXZxNQjQUKV4eRhx9zdJQEwAtAHKNFEQiwCMNP33_d3sU4MGeh03adAp4l-eSLOagwDGNrLQ7JLS17TLCVuFlsfgAKxsvEY9gSuWILcV3z6sw6oLS_kxaCdu5LdnL08duHYdKlfUiMEBVPpCwLjSORlTa3iCOjBLIO55A5GqtT71OuvRpgJVcJbRTHCYK0LmSq4SpPB6_YZjNq3C4DoazjzqSZMl4onZdVSpAtSeQorXTRY3zxietxVPeoV2ZFZU29Trk6qzr0en3dY7DAQo2mSP9XVONGs2ldkJoil2n1cJWKHAwpHPXY6wijP_etZInzbzyTBzD88wPV-NGwsPfI696wrRgRQSE6b9lmO5m5d0i0Wv0-mNBvYbcezw |
link.rule.ids | 315,786,790,1382,27957,27958,46329,46753 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQIgEX3o_ynAPXVHHqOAm3FWLVhe0e0C7am-WntNqSrropUE78BO78O34JM3Za1AISQlwiS3GcxPnG88j4G8aeo5FajELNs9oHmYmi0JmuKp7ZII0MBR4EbXCeHMrxsXh9Up705YBoL0zih1gH3Egy4npNAk4B6W0pRxcIFdaKd7Iq-RANysso_WX0r96uuaR4NYoBF7xGZKiVttJ6fjvSpq76xQDdtGejQtq7waarV0l5KGfDRWeG9vMWy-N_eteb7HpvuMJuQtotdsm3t9mVSf9r_g77tmu01R9O56BbB5SxDrMA75eoKwmDU0Aoo1ARDrAJ4_133798Talg3kFP73oBeJYYlKdL0HElxtE6XJU7inzMcZS0X2z5AjScr2uP4UikjR2k0ObHU-eBKv_OO4j0uXfZ8d6ro5fjrK_8kFkhGp5JWVcGFyMnXekQSlYLNDy8R-PROpOHkHMT9Ag7-UYYqzn6CNL5WKyG6zIf3WM77az1DxgI7Tz3Ni-0DUKbsm5yQm1NPEd5Y6oB46tvrM4TwYfacIxqRbNO5TobFWddfRowWIFBoTTSLxbd-tniQlVEqMhl3vy5S0M6hkiOBux-wtHP-zayRhccz5QRDX_9QAo_GjYe_uN1z9jV8dHkQB3sH755xK6lBAnK2HnMdrr5wj9Bu6szT6M8_QBWXyLx |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELaqIlVcoJTXtjx84JpVnDhOwq1qWW2hrRCiqDfLT6lqm11ts4XlxE_onX_HL2HGzm61C0gIcYksxXZi-xvP2B5_Q8grMFKz3FcsqZwXCc8ylaiyZInxQgufwYPjBeejYzE84W9Pi9PO_wnvwkR-iMWGG0pGmK9RwMfWrwo5rIBAX81pJ8uC9cGevMNFniHC9z8sqKRYmYf9FijDE1BKK149v61pWVX9Yn8um7NBHw3uk_N5S6Ibynl_2uq--bpC8vh_mrpJ7nVmK92NOHtA1lyzRTaOuoP5h-T7rlZGXZ9NqGosRX91OvL0cgaaEhF4QQHIIFKIAkjS4cGnH99uoiOYs7Qjd72i8Bb5ky9mVIV5GGprYU5ucd9jArXE22Kz11TR8SLyGNSEutjSuLH5-cw6inF_Jy0N5LmPyMngzce9YdLFfUgM5zVLhKhKDVORFbawACSjOJgdzoHpaKxOvU-Z9iqHTK7m2igGKwRhXQhVw1SR5o_JejNq3FNCubKOOZNmyniudFHVKWK2QpajtNZlj7D5EMtxpPeQS8uiSmKvY7DOWoZel196hM6xIEEW8YBFNW40vZIl0ikykdZ_zlKjhkGKox55EmF0-91aVLAAhzdFAMNf_5CEQYPE9j-We0k23u8P5OHB8bsdcjd6R6C7zjOy3k6m7jkYXa1-EaTpJ89MIaA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Abacavir+and+risk+of+myocardial+infarction+in+HIV-infected+patients+on+highly+active+antiretroviral+therapy%3A+a+population-based+nationwide+cohort+study&rft.jtitle=HIV+medicine&rft.au=Obel%2C+N&rft.au=Farkas%2C+D+K&rft.au=Kronborg%2C+G&rft.au=Larsen%2C+C+S&rft.date=2010-02-01&rft.issn=1464-2662&rft.volume=11&rft.issue=2&rft.spage=130&rft.epage=136&rft_id=info:doi/10.1111%2Fj.1468-1293.2009.00751.x&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-2662&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-2662&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-2662&client=summon |